Case Analysis Intra‑Cellular Therapies, Inc. v. Controller of Patents (Delhi High Court, 2026)
I. Overview and Procedural Posture The Delhi High Court, in an appeal under Section 117A of the Patents Act, 1970, upheld the Controller's rejection (order dated 27.04.2023) of the patent application (No. 201817033732) titled "Organic Compounds" and covering deuterated heterocycle-fused gamma-carboline compounds (Formulas I–IV). The claims fell into two clusters: Claims 1–3 & 5–10 (Formula I–III compounds) and Claims 4 & 5–7 (Formula IV compounds), with Claim 11 as a dependent pharmaceutical composition claim. The claimed invention was for the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signalling systems and also has application in the treatment of diseases/disorders like anxiety, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, etc. The rejection rested on lack of novelty (Section 2(1)(j)), obviousness (Section 2(1)(ja)), and non-patentability under Sect...